Holen Sie sich die Stockscreener-App
40.73
2.16%
0.86
Handel nachbörslich:
40.73
Schlusskurs vom Vortag:
$39.87
Offen:
$40.38
24-Stunden-Volumen:
831.58K
Relative Volume:
0.98
Marktkapitalisierung:
$2.65B
Einnahmen:
$58.89M
Nettoeinkommen (Verlust:
$-240.88M
KGV:
-13.14
EPS:
-3.1
Netto-Cashflow:
$-239.96M
1W Leistung:
-1.50%
1M Leistung:
-8.43%
6M Leistung:
+11.19%
1J Leistung:
-5.28%
1-Tages-Spanne:
$39.71
$41.81
1-Wochen-Bereich:
$36.65
$41.81
52-Wochen-Spanne:
$19.45
$53.27
Kymera Therapeutics Inc Stock (KYMR) Company Profile
Firmenname
Kymera Therapeutics Inc
Sektor
Branche
Telefon
857-285-5314
Adresse
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Vergleichen Sie KYMR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KYMR
Kymera Therapeutics Inc
|
40.73 | 2.85B | 58.89M | -240.88M | -239.96M | -3.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-30 | Fortgesetzt | B. Riley Securities | Buy |
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-06-03 | Hochstufung | B. Riley Securities | Neutral → Buy |
| 2025-06-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-06-02 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-05-20 | Fortgesetzt | Stifel | Buy |
| 2025-03-13 | Eingeleitet | Citigroup | Buy |
| 2024-12-10 | Eingeleitet | BTIG Research | Buy |
| 2024-12-06 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2024-12-02 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | Eingeleitet | Stephens | Overweight |
| 2024-09-09 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-08-26 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2024-04-22 | Eingeleitet | Oppenheimer | Outperform |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-01-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-12-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-06-30 | Eingeleitet | Truist | Buy |
| 2023-05-05 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2022-12-06 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-11-08 | Eingeleitet | Raymond James | Mkt Perform |
| 2022-08-15 | Eingeleitet | Jefferies | Buy |
| 2022-08-03 | Eingeleitet | Goldman | Buy |
| 2022-07-20 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-04-28 | Eingeleitet | Credit Suisse | Outperform |
| 2022-03-10 | Eingeleitet | JP Morgan | Neutral |
| 2022-02-10 | Eingeleitet | Wells Fargo | Overweight |
| 2021-09-30 | Eingeleitet | B. Riley Securities | Neutral |
| 2021-09-30 | Eingeleitet | Stifel | Buy |
| 2021-09-10 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-04-14 | Eingeleitet | Berenberg | Buy |
| 2020-12-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-09-15 | Eingeleitet | BofA Securities | Neutral |
| 2020-09-15 | Eingeleitet | Cowen | Outperform |
| 2020-09-15 | Eingeleitet | Guggenheim | Buy |
| 2020-09-15 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Kymera Therapeutics Inc Aktie (KYMR) Neueste Nachrichten
Hatteras Venture Partners Raises Over $200 Million in Capital Across Two Healthcare-Focused Funds - GlobeNewswire Inc.
Kymera Therapeutics Second Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Kymera Therapeutics’ Earnings Call: Optimism and Strategic Progress - TipRanks
Kymera Therapeutics: Promising Developments in STAT6 Degrader KT-621 Drive Buy Rating - TipRanks
Kymera extends cash runway to 2H 2028 as immunology pipeline advances and collaborations boost funding - MSN
Kymera Therapeutics Inc (KYMR) Q2 2025 Earnings Call Highlights: Strategic Collaborations and ... - Yahoo Finance
Kymera Therapeutics Reports Q2 2025 Progress and Partnerships - TipRanks
Kymera Therapeutics shares fall 1.14% after-hours after reporting a widened Q2 loss and falling collaboration revenue. - AInvest
Kymera Therapeutics Q2 2025: Unpacking Contradictions in Clinical Expectations, Safety Monitoring, and Dosing Strategies - AInvest
Kymera Therapeutics: Strategic Catalysts and Monetization Potential in a High-Stakes Biotech Landscape - AInvest
Kymera Therapeutics Q2 2025 Earnings Call Transcript - MarketBeat
Transcript : Kymera Therapeutics, Inc., Q2 2025 Earnings Call, Aug 11, 2025 - MarketScreener
Kymera Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings call transcript: Kymera Therapeutics Q2 2025 results miss forecasts By Investing.com - Investing.com UK
Kymera Q2 2025 slides: Strong pipeline advances despite revenue decline By Investing.com - Investing.com Australia
Kymera Q2 2025 slides: Strong pipeline advances despite revenue decline - Investing.com
Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Kymera Revenue Drops 55 Percent in Q2 - The Globe and Mail
Kymera’s Losses Widen But Wall Street Stays Optimistic - Finimize
Kymera Therapeutics, Inc. SEC 10-Q Report - TradingView
Kymera Therapeutics' Q2 2025 Earnings Miss: A Test of Resilience in the TPD Space? - AInvest
Kymera Therapeutics Q2 Loss Widens, Collaboration Revenue Falls - MarketScreener
Earnings Flash (KYMR) Kymera Therapeutics, Inc. Reports Q2 Revenue $11.5M, vs. FactSet Est of $22.2M - MarketScreener
Earnings Flash (KYMR) Kymera Posts Q2 Loss $0.95 a Share, vs. FactSet Est of $0.89 Loss - MarketScreener
Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update - The Manila Times
Kymera Therapeutics Q2 revenue misses expectations, net loss widens - TradingView
Kymera Reports Phase 1 Success, Secures $750M Gilead Partnership with $1B Cash Position | KYMR Stock News - Stock Titan
Gilead Sciences Signs $750M Deal For Cancer Drug With Kymera Therapeutics, Predicts Hit To Its Annual Profit - MSN
Kymera Therapeutics Earnings Preview: What to Expect - AInvest
Kymera Therapeutics KYMR Q2 2025 Earnings Preview Upside Potential Driven by Strategic Partnerships - AInvest
Earnings To Watch: Kymera Therapeutics Inc (KYMR) Reports Q2 2025 Result - Yahoo Finance
Kymera Therapeutics Becomes Oversold (KYMR) - Nasdaq
Earnings Preview: KYMR to Report Financial Results Pre-market on August 11 - 富途牛牛
Kymera Therapeutics to Report Second Quarter 2025 Financial Results on August 11, 2025 - The Manila Times
Kymera Therapeutics reports Q2 2025 results, plans call on August 11. - AInvest
Clinical-Stage Biotech Kymera Therapeutics Sets Q2 Earnings Date: Key Updates Expected on Immunology Pipeline - Stock Titan
Is Kymera Therapeutics Inc. a growth stock or a value stockFree Investment Community - Jammu Links News
How does Kymera Therapeutics Inc. generate profit in a changing economyTransform your portfolio with high-yield stocks - Jammu Links News
What catalysts could drive Kymera Therapeutics Inc. stock higher in 2025Get expert analysis on top stock picks - Jammu Links News
What makes Kymera Therapeutics Inc. stock price move sharplyAchieve consistent profits with proven methods - Jammu Links News
Should I hold or sell Kymera Therapeutics Inc. stock in 2025Dynamic portfolio growth - Jammu Links News
How many analysts rate Kymera Therapeutics Inc. as a “Buy”Stay ahead with daily market updates - Jammu Links News
Why is Kymera Therapeutics Inc. stock attracting strong analyst attentionUnlock powerful trading tools for investors - Jammu Links News
What is Kymera Therapeutics Inc. company’s growth strategyExplosive earning power - Jammu Links News
What analysts say about Kymera Therapeutics Inc. stockCapitalize on emerging trends for profits - Jammu Links News
How strong is Kymera Therapeutics Inc. company’s balance sheetSwing Trade Review With Proven Results - Jammu Links News
Kymera Therapeutics: A Biotech Company with a Promising Future - AInvest
Is it the right time to buy Kymera Therapeutics Inc. stockBreakout Stocks Ideas For 2025 - Jammu Links News
Gilead, Kymera Partner in $750M Deal to Develop Novel Molecular Glue Degraders for Cancer - MSN
Kymera Therapeutics Inc. Chart Enters High Volatility ZoneSecure Return Focused Investment Plan Released - metal.it
Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release - Yahoo Finance
Finanzdaten der Kymera Therapeutics Inc-Aktie (KYMR)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):